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Summary Malignant progression of tumour cells is caused by the accumulation ofgenetic defects, which when
combined will generate a large phenotypic diversity. Simultaneous quantitation of a large number of gene
products in tumour cells is desirable, but difficult to achieve. We have here quantitated the levels of a number
of abundant polypeptides in human breast carcinoma cells using two-dimensional gel electrophoresis (2-DE;
PDQUEST). For this purpose, tumour cells were prepared from the tissue of 17 breast carcinomas.
Fibroadenoma tissue was used as reference for benign cells. An increase of the spot density of the PCNA
polypeptide was observed in rapidly proliferating tumour cells, confirming the validity of the procedures used.
In the set of 24 polypeptide spots with known identity, decreases in cytokeratin and tropomyosin levels were
observed. The levels of all cytokeratin forms resolved (CK7, CK8, CK15 and CK18) were significantly lower in
carcinomas than in fibroadenomas. The levels of tropomyosin 2 and 3 were lower in carcinomas than in
fibroadenomas. In contrast, the levels of some members of the stress protein family (pHSP60, HSP90 and
calreticulin) were higher in carcinomas. Furthermore, changes in the expression of lactate dehydrogenase and
GT-i, but not in nm23, were observed. We conclude that simultaneous analysis of multiple polypeptides in
human carcinomas can be achieved by 2-DE and may be useful in prognostic studies, and that malignant
progression of breast carcinomas results in the decreased expression of cytokeratin polypeptides. This
phenomenon must be considered in studies where cytokeratins are used as markers to identify the epithelial cell
compartment in breast carcinomas.
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Breast cancer is both biologically and clinically a hetero-
geneous disease. Although presenting without evidence of
disseminating cancer, a proportion of women will die rapidly
in metastatic disease. In spite of enormous efforts in breast
cancer research, three main problems remain: (1) to
objectively and reliably select those premalignant lesions
which, if untreated, will progress to invasive malignancy; (2)
to objectively and reliably determine the aggressiveness of an
individual tumour and (3) to analyse cellular properties which
allow highly individualised tumour-specific treatment.
Two-dimensional gel electrophoresis (2-DE) is a technique
which can be used to obtain qualitative and quantitative
information on protein expression in cells. In a recent update
of the two-dimensional protein database, 1082 proteins were
reported to be identified by name (Celis et al., 1995).
Identification is aided by recent progress in microsequen-
cing, including mass spectrophotometry. We have here
explored 2-DE to characterise polypeptide profiles in human
breast carcinomas. Major polypeptides in the gel profiles were
identified (mostly cytoskeletal and stress-related proteins) and
quantified. We describe alterations in the expression of some
of these polypeptides. We show that the levels of several
cytokeratin polypeptides are lower in carcinomas than in
fibroadenomas. These results suggest that 2-DE can be a
valuable future tool for the characterisation of gene
expression in human malignant tumours.
Materials and methods
Tumour tissue samples
All samples, described in Table I, were obtained shortly
after resection and processed essentially as described below
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(Franzen et al., 1993). Cells were purified from non-necrotic
tumour tissue within 40 min after resection, and all steps
were performed on ice in the presence of protease inhibitors.
Each resected tumour was placed on ice, cut in the middle
and one (or two) macroscopically representative and non-
necrotic area was selected for extraction of cells. The surface
of a freshly cut tumour was scraped with the dry blade of a
sharp scalpel. As previously discussed, tumour cells are more
loosely attached to the extracellular matrix than normal cells
and will be preferentially extracted. Cells were collected in 1-
2 ml of ice-cold medium (RPMI-1640) supplemented with
5% calf serum/protease inhibitors (0.2 mM phenylmethylsul-
phonyl fluoride and 0.83 mM benzamidine). Cell suspensions
were first filtered using a 250 ,im filter directly followed by a
100 jMm nylon mesh to remove tissue fragments. Cell
suspensions were then collected in new tubes and carefully
underlaid with 1.0- 1.5 ml of ice-cold Percoll phosphate-
buffered saline (PBS) solution (54.7%, density 1.07 g ml-1)
and finally centrifuged for 10 min at 1000 g and 4°C. The
interface cell layers were washed with PBS and pelleted. The
wet weight of each cell pellet was recorded and cells were
then stored at -80°C. The final preparation of cell pellets
was performed according to Linder et al. (1979) and Garrels
et al. (1979), with some modifications (Franzen et al., 1993).
Adjacent material was fixed in 4% buffered formalin and
embedded in paraffin.
Characterisation offormalin-fixed specimens
Malignant tumours were subdivided into two subgroups on
the basis of proliferative index and DNA ploidy assessments.
Proliferation index was determined by immunohistochemical
staining using the MIB-1 antibody (Immunotech). The
fraction of positive cells was scored and classified as 'low'
(<20%), 'intermediate' (20-50%) and 'high' (>50%).
Histopathology (using haematoxylin-eosin-stained sections)
was performed by one experienced pathologist and classified
according to WHO. The nuclear DNA content was assessed
using image cytometric analysis of Feulgen-stainedPolypeptide expression in human breast lesions
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Table I Clinical data and characteristics of the samples analysed
Case Histopathological Patient Size Histopathological Proliferation Lymph nodes
No. Diagnosis age (years) (mm) Differentiationa (MIB-J)b positive/total
Non-malignant lesions
141 Normal - - - ND -
122 Fibroadenoma 21 20 - L -
124 Fibroadenoma 20 20 - IM -
127 Hamartoma 32 25 - L -
128 Fibroadenoma 32 7 - L -
139 Fibroadenomatosis 20 17 - IM -
140 Fibroadenoma 20 50 - ND -
DNA-diploid and low-proliferative invasive carcinomas
012 78 22 M L 0/4
071 66 14 P L 0/3
088 78 27 M L 0/4
119 82 20 W L 0/11
133 43 16 M L 0/8
022 49 40 W L 1/7
065 69 18 M L 1/9
066 74 17 W L 1/9
093 72 20 P L 2/9
DNA-aneuploid and intermediate/high-proliferative invasive carcinomas
123 41 24 P H 0/12
126 84 18 P H 0/7
135 36 25 P H 0/8
053c 86 47 P IM d
060 78 70 P H 7/7
080 73 15 P H 1/4
083 81 20 P H 4/6
116 78 110 P IM 8/10
aHistopathological differentiation: P, poor; M, moderate; W, well. bProliferation (MIB 1): L, low (0-20% positive
tumour cells); IM, intermediate (20-50%); H, high (>50%). 'Mixed type, mucinous. dDistant metastases in the skeleton
found. ND= not determined.
cells.Tumours with a single stem line in the diploid region
were classified as diploid, and tumours with pronounced
scattered DNA values exceeding the tetraploid region were
classified as aneuploid (Auer et al., 1980). Normal
lymphocytes were used as internal 2c reference cells.
Tumours with unclear classification were excluded from the
study (12 cases).
Electrophoresis
2-DE was performed by standard procedures as described
previously (Franzen et al., 1993; Anderson et al., 1992).
Resolyte (2%, pH 4-8; BDH) was used for isoelectric
focusing, and 10-13% linear gradient sodium dodecyl
sulphate (SDS) polyacrylamide gels in the second dimen-
sion. Gels were stained with silver nitrate according to
standard procedures.
Identification ofpolypeptides
A number of polypeptide spots were identified by matching
with published maps and/or exchanging samples with other
investigators. A rat embryonal fibroblast cell line WT2 (a
kind gift from Drs JI Garrels and S Pattersson, Cold Spring
Harbor, NY, USA) was used for the identification of a
number of heat shock and structural proteins. 2-DE maps
were prepared from WT2 cells and matched with the REF52
database (Garrels et al., 1989). 2-DE maps were prepared
from pre-B-ALL cells (clinical sample of acute lymphatic
leukaemia) and subsequently analysed by Dr SM Hanash
(University of Michigan, Ann Arbor, MI, USA). In
addition, 2-DE maps were prepared from MRC-5 cells
(cell lysate provided by JE Celis) and analysed by JE Celis
(Aarhus University, Denmark).
The identity of some polypeptides was confirmed by
purification-enrichment. Tropomyosins were purified as
described by Matsumura et al. (1985) from W138
fibroblasts. The identification of GT(ir) was confirmed by
an in vitro drug resistance experiment, where vincristine-
resistant human K562 cells (cell pellets provided by S Vitols,
Karolinska Institutet, Stockholm) were found to overexpress
the polypeptide which had tentatively been identified as
GT(7r). Cytokeratins were extracted from MCF-7 cell lysates
(Paulin et al., 1980). Proliferating cell nuclear antigen
(PCNA) was identified by immunoblotting (PC1O MAb,
Dakopatt) using a semi-dry system (Multiphor II Nova Blot,
Pharmacia Biotech AB) and electrochemiluminescence
detection (Amersham).
Scanning and image analysis
2-DE gels were scanned at 100 gm resolution using
Molecular Dynamics laser densitometer. Data were analysed
using the PDQUEST software (Garrels et al., 1984)
(Pharmacia Biotech, Uppsala, Sweden). A synthetic 'identi-
fication reference pattern' including at least all identified
spots was constructed. In subsequent analyses, polypeptide
spots were matched to spots in the reference pattern using the
PDQUEST software (construction of a 'matchset'). Back-
ground was subtracted, peaks located and the individual
polypeptide quantities were expressed as p.p.m. of the total
integrated optical density. Three groups were constructed
within the matchset: benign lesions, DNA-diploid/low-
proliferative tumours and DNA-aneuploid/high-proliferative
tumours. The level of polypeptide expression in each group
was calculated as the mean value (+standard deviation) of
normalised p.p.m. values. We used the Mann-Whitney non-
parametric test for determination of significant differences at
the levels of P<0.05.
Results
Analysis ofpolypeptide expression in breast cancer lesions
A total of 23 lesions were examined. Of these, six cases were
non-malignant (four fibroadenomas) and 17 cases were
rsp
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Figiure 1 Reference 2-DE gel profile assembled from breast carcinomas and MDA-MB-231 breast cells. Acidic polypeptides are to
the left. Polypeptides with known identity are encircled. Polypeptides with names within brackets were tentatively identified.
invasive, ductal breast carcinomas (Table I). Carcinomas
were divided into two groups: (1) slowly proliferating and
diploid tumours and (2) rapidly proliferating and aneuploid
tumours as described in Materials and methods. The
histopathological characteristics of all cases are presented
in Table I. Cases not conforming to this classification were
not considered.
Cells were extracted from fresh tumour tissue and single-cell
suspensions free of erythrocytes were prepared as previously
described (Franzen et al., 1993; see Materials and methods).
These preparations were usually >90% tumour cells. Samples
were prepared for two-dimensional gel electrophoresis (2-DE).
Thepolypeptide patternswereanalysed byPDQUESTsoftware
(Garrels et al., 1984), and the levels of individual polypeptides
were expressed as p.p.m. The identity of individual spots was
ascertained by co-electrophoresis ofpurified polypeptides and/
ormatching with databases (see Material andmethods). Shown
in Figure 1 is a 'reference pattern' assembled from tumours and
one breast cancer cell line (MDA-MB-231).
Evaluation of 2-DE gelsfrom non-malignant and malignant
breast lesions
Figure 2 shows representative examples of gels derived from a
fibroadenoma, a slowly proliferating carcinoma and a rapidly
proliferating carcinoma. A 'window' of neutral to acidic
proteins in the 25-100 kDa range is shown. Differences in
polypeptide expression will be discussed below for various
polypeptides of which the identities are known (encircled in
Figures 1 and 2). Mean values of spot intensities in different
groups of lesions are presented in Table II.
Cell cycle-related proteins
The recorded spot intensity ofPCNA (proliferating cell nuclear
antigen) was found to reflect the proliferative status of the
tumours. PCNA levels were 4.3-fold higher (significant, see
Materials and methods) in highly malignant tumours than in
non-malignant cells (TableII). The distribution ofPCNAlevelsPolypeptide expression in human breast lesions
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Figure 2 2-DE profiles from (a) a case of fibroadenoma, (b) a case of slowly proliferating carcinoma and (c) a case of rapidly
proliferating carcinoma.
Table II Polypeptide expression in breast lesions. The levels of individual polypeptides are expressed as p.p.m. of total polypeptides
Polypeptide
PCNA
Opl8
Tropomyosin 1 (TM1)
Tropomyosin 2 (TM2)
Tropomyosin 3 (TM3)
Cytokeratin 8 (CK8)
Cytokeratin 18 (CK18)
Heat shock protein27 (hsp27)
Heat shock protein60 (hsp60)
Hsp60, phosphorylated (phsp60)
Heat shock protein73 (hsp73)
Heat shock protein90 (hsp90)
Calreticulin (CALR)
Mitcon3
eIF5A
EF1I
LDH
AnnexinV
nm23
SOD
GT(n)
Benign
lesions
Mean+s.d. (n=6)
90+59
77
747+285
485+ 135
1419+385
6158 +4088
3685+ 1603
1687+828
4120+ 1111
1669+750
3422+936
658+423
7104+2356
3462+855
1027+596
2325+609
1622+639
4005+1013
711+359
1316+857
2381+ 1106
aFold change relative to the mean value level ofbenign lesions.
Levels
Diploid/low
proliferative lesions
Mean+s.d. (n =9)
328+218 (1.73)a
21 (0.27)
172+ 152
50
476+251
1895+ 1142
681 +682
954+386
5068+ 1498
2401 +958
4473+1998
1198+ 1211
7569+3080
3769+1830
958+ 1637
2265+801
1881 +915
3326+ 1767
1008+416
2074+999
1679+2191
(0.23)
(0.10)
(0.33)
(0.31)
(0.18)
(0.56)
(1.23)
(1.44)
(1.31)
(1.82)
(1.07)
(1.09)
(0.93)
(0.97)
(1.16)
(0.83)
(1.42)
(1.58)
(0.70)
Aneuploid/high
proliferative lesions
Mean+s.d. (n =8)
821+341 (4.32)a
238 (3.09)
503+395
149
638+449
1107+ 1004
751+794
2002+ 1042
5574+ 1521
3618+ 1085
4964+3854
1303+770
11961+7143
3313+2196
946+785
1604+720
1661+710
5051 +3566
814+391
1777+ 1031
1460+1127
(0.71)
(0.30)
(0.45)
(0.18)
(0.20)
(1.19)
(1.35)
(2.17)
(1.45)
(1.98)
(1.68)
(0.96)
(0.92)
(0.69)
(1.02)
(1.26)
(1.14)
(1.35)
(0.61)
in various samples is shown in Figure 3. Opl8 (oncoprotein 18/
stathmin) is a phosphoprotein believed to have a regulatory
role in the cell cycle. Opl8 could not be detected in eight out of
nine slowly proliferating/diploid tumours, but was detected in
five out of eight rapidly proliferating/aneuploid tumours
(Figure 3). Higher Opi8 levels were found in non-malignant
lesions than in slowly proliferating carcinomas (Table II).
Cytoskeletal proteins
A number of cytoskeletal proteins were identified in the
polypeptide maps. These include actin, tropomyosin 1-5, a-
actinin, a- and f- tubulin and cytokeratins 7, 8, 15 and 18.
Some of these proteins were not well resolved from
neighbouring spots, others could not be quantified because
of overstaining. The identity of cytokeratin 8 and 18 could be
confirmed by extracting cytoskeletal polypeptides from MCF-
7 breast carcinoma cells (Figure 4). Cytokeratins 7 and 15
were tentatively identified by their (1) migration properties
(spot position), (2) absence in fibroblasts, and (3) enrichment
in cytoskeletal fractions from tumours. Tumour cytoskeleton
preparations were, however, contaminated by cytosolic
proteins, and the identification of cytokeratins 7 and 15 is
considered as tentative. Cytokeratin 19 was identified using
the MCF-7 extract but was not included in the analysis
because of possible comigration with a large number of
neighbouring spots in most of the cases.
All four forms of cytokeratins resolved were found to be
expressed at lower levels (significant) in carcinomas than in
fibroadenomas (Table II). The levels of cytokeratin 8 and 18
in individual tumours is shown in Figure 4. In 12 out of 17
carcinomas, cytokeratin 18 could not be detected due to low
expression.
Tropomyosin levels were lower in carcinomas than in non-
malignant cells, confirming our previous findings (Franzen et
al., 1996). In the material analysed here, the decreases in
tropomyosin 2 and 3 were statistically significant, but not
that of tropomyosin 1.Polypeptide expression in human breast lesions
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Figure 3 Levels of polypeptides in individual tumours. Shown are the relative levels ofcytokeratin 8 (CK8), cytokeratin 18 (CK18),
proliferating cell nuclear antigen (PCNA), oncoprotein 18 (Opl8), tropomyosin 2 (TM2), tropomyosin 3 (TM3), heat shock protein
90 (HSP90) and phosphorylated heat shock protein 60 (pHSP60).
Stress proteins
Overexpression of some stress proteins, such as HSP90 and
HSP27, have been associated with malignancy. We noticed
a moderate increase in HSP90 (1.6-fold) and calreticulin
(1.7-fold) in highly malignant cancers. HSP27 levels did
not, in contrast, differ between carcinomas and non-
malignant cells.
Whereas the levels of HSP60 showed small variations (1.3-
fold higher in rapidly proliferating carcinomas), the levels of
the phosphorylated form of this gene product, pHSP60, were
2.2-fold increased in rapidly proliferating carcinomas. This
increase was statistically significant.
nm23
nm23 (Nucleotide diphosphate kinase) levels have been
reported to be low in metastatic cells (Steeg et al., 1993). A
weak, but not significant, increase in nm23 levels was
preferentially recorded in slow proliferating carcinomas. In
the material analysed here, we could not find any association
with lymph node status.
Glutathione S-transferase 7t
GT-7r has been implicated in tumour progression and in
resistance to chemotherapy (Daniel et al., 1993). In the
material studied here, GT-7 levels were somewhat lower in
malignant cells than in fibroadenomas. This difference was
not statistically significant.
Constitutively expressed proteins
The levels of a number of identified proteins did not differ
(less than 50% change) between groups. Mitcon3 (mitochon-
drial), eIF5A (initiation factor SA), LDH (lactate dehydro-
genase form M), annexin V and EFlb (elongation factor 1I
belonged to this category.
Discussion
Analysis of polypeptide profiles in human tumours is not a
trivial task. Samples may contain relatively large amounts of
protein from other cell types present in the tumours, such as
Figure 4 Purification of cytokeratins from MCF-7 breast
carcinoma cells. 2-DE gels showing (A) total proteins and (B)
extracted intermediate filaments are shown.
stromal fibroblasts and lymphocytes. Furthermore, massive
contamination by serum proteins may preclude large areas
of the maps. These problems can be circumvented by
purifying viable tumour cells from freshly excised tumours
(Franzen et al., 1993). We have studied here the expression
of 24 polypeptides with known identity (by name) in breast
carcinomas and show that changes in the levels of some of
these polypeptides can be demonstrated. As more than 1000
polypeptides have been identified in the human 2-DE map
(Celis et al., 1995), it will be possible to make detailed
characterisations of changes in gene expression in tumours
in the future.
Tumours were classified as slowly proliferating/diploid or
rapidly proliferating/aneuploid. Using this classification, we
were convinced that the procedures used were sufficiently
accurate to detect changes in the levels of proliferation
markers. The levels of the PCNA polypeptide were found to
increase in parallel with progression from non-malignant
lesions to slowly proliferating and then to rapidly
proliferating carcinomas. Similarly, oncoprotein 18 levels
were 3-fold higher in rapidly growing tumours than in
fibroadenomas.
Trask et al. (1990) reported that normal cultured breast
epithelial cells produce cytokeratin 5, 6, 7, 14 and 15,
whereas tumour cells produce mainly cytokeratin 8, 18 and
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19. We found cytokeratins 7, 8, 15 and 18 to be expressed in
fibroadenomas. This result suggests that alterations in
cytokeratin expression occur early during neoplastic
transformation and is consistent with the finding of low
levels of cytokeratin 5 and high levels of cytokeratin 18 in
immortalised breast cell lines (Trask et al., 1990). The levels
of cytokeratin 7, 8, 15 and 18 were significantly lower in
carcinomas than in fibroadenomas. Decreases in cytokeratin
immunostaining in breast cancer have been previously
described (Wada et al., 1991; Takei et al., 1995; Heatley et
al., 1995). Takei et al. (1995) reported that cytokeratin 8
(CK8) staining was negative in 35% of invasive breast
carcinomas examined, and that the absence of CK8
correlated with oestrogen receptor negativity. Similarly,
Heatley et al. (1995) reported that some carcinomas are
negative for cytokeratins 7, 8 or 18. Paine et al. (1992)
showed that in vitro transformation of MCF-1OA cells with
ras-oncogenes decreased the levels of cytokeratins 7, 8, 15
and 16. Our data extend previous reports, as we can
demonstrate decreases in cytokeratins in ex vivo tumour cells
by measurements of polypeptide levels. We can exclude the
possibility that previously reported decreases in immunos-
taining could be explained by the masking of epitopes or as
the result of immunohistochemical artifacts.
Cytokeratins are used as markers to identify breast
carcinoma cells in various situations (for a review, see
Moll et al., 1991). In two colour multiparametric flow
cytometry analyses, the epithelial cell compartment is
identified by cytokeratin antibodies, and DNA histograms
can be specifically obtained from these cells (Ramaekers et
al., 1984; Wingren et al., 1994). MAbs to cytokeratins have
been used to detect epithelial tumour cells that have
metastasised from primary adenocarcinomas to secondary
sites such as the bone marrow (Pantel et al., 1993; Harbeck
et al., 1994). Pantel et al. (1993) reported that the incidence
of metastatic cells in bone marrow was 74% in breast cancer
patients known to have macroscopical metastases. Decrease
or loss of cytokeratins in carcinomas can potentially be a
problem in these types of studies, as the most malignant
cells may escape detection.
Deregulation of tropomyosin expression has been shown
to contribute to morphological transformation in experi-
mental systems. It was recently suggested that Fos
oncoproteins induce deregulation of genes encoding cytoske-
leton-associated proteins (Jooss et al., 1995). We have
previously observed down-regulation of tropomyosin 1-3
in breast carcinoma tissue (Franzen et al., 1996). In the
present study, significant down-regulation was observed for
tropomyosin 2 and 3. In one of the tumours, high
tropomyosin expression was observed (see Figure 3).
Whether tropomyosin in these cells was due to contaminat-
ing, non-malignant cells or due to expression in tumour cells
is not clear.
Increases in various stress proteins were found in
carcinomas, but these were less than 2-fold. HSP-27 has
been reported to be overexpressed in 25% of invasive ductal
carcinomas, and overexpression in early-stage breast cancer
is associated with poor prognosis. In addition to being
induced by heat shock, HSP90 may be induced by
transformation by ras (Lebeau et al., 1991). HSP90 may
also regulate DNA-binding activities of progesterone
receptors in breast cancer cells. In previous studies, we
observed elevated levels of HSP90 in potentially highly
malignant breast tumours and in small-cell lung carcinomas
(Okuzawa et al., 1994) using 2-DE.
We conclude from this study that 2-DE can be used to
study complex changes in gene expression occurring in
tumours. We believe that with the advent of standardised
2-DE techniques and 2-DE data bases, this approach may be
a useful complement to other techniques, such as cDNA
library screening.
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